Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans. (3rd April 2021)
- Record Type:
- Journal Article
- Title:
- Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans. (3rd April 2021)
- Main Title:
- Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans
- Authors:
- Wang-Lakshman, Lydia
Mendonza, Anisha E.
Huber, Roland
Walles, Markus
He, YanLing
Jarugula, Venkateswar - Abstract:
- Abstract: Absorption, metabolism, and excretion (AME) of licogliflozin, a sodium-glucose co-transporters (SGLTs) 1 and 2 inhibitor, were studied in male rats, dogs, and healthy male volunteers and reported. Oral absorption of licogliflozin was rapid ( t max < 1 h) with absorption estimated at 87%, 100% and 77% in rats, dogs and humans, respectively. Excretion of licogliflozin-related radioactivity was rapid and nearly complete following oral administration with total radioactivity recovery ranging from 73% in dogs, 92.5% in humans, to 100% in rats. Dose-related radioactivity was excreted in both urine and faeces with urinary excretion playing a slightly more important role in humans (∼56%) than in animal species (∼19–41%). Elimination of licogliflozin was predominantly via metabolism with the majority of the radioactivity dose (∼54–74%) excreted as metabolites across species. The principal biotransformation pathways involved direct glucuronidation and oxidation across all species. In humans, direct glucuronidation to M17 and M27 was the major pathway observed, accounting for ∼38% of the dose in excreta while oxidative metabolism also contributed to >29% of the dose in excreta. Oxidative pathways were predominant in animal species.
- Is Part Of:
- Xenobiotica. Volume 51:Number 4(2021)
- Journal:
- Xenobiotica
- Issue:
- Volume 51:Number 4(2021)
- Issue Display:
- Volume 51, Issue 4 (2021)
- Year:
- 2021
- Volume:
- 51
- Issue:
- 4
- Issue Sort Value:
- 2021-0051-0004-0000
- Page Start:
- 413
- Page End:
- 426
- Publication Date:
- 2021-04-03
- Subjects:
- SGLT1/2 inhibitor -- AME -- biotransformation -- glucuronidation -- oxidative metabolism
Metabolism -- Periodicals
Drugs -- Physiological effect -- Periodicals
Food additives -- Periodicals
Chemicals -- Physiological effect -- Periodicals
Biochemistry -- Periodicals
Pharmaceutical Preparations -- metabolism -- Periodicals
Metabolism -- Periodicals
574.133 - Journal URLs:
- http://informahealthcare.com/journal/xen ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/00498254.2020.1867331 ↗
- Languages:
- English
- ISSNs:
- 0049-8254
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9367.020000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 23445.xml